CTIM-12. RANDOMIZED PHASE 2 STUDY OF NIVOLUMAB (NIVO) PLUS EITHER STANDARD OR REDUCED DOSE BEVACIZUMAB (BEV) IN RECURRENT GLIOBLASTOMA (rGBM)

BACKGROUND: Trials with anti-PD1 in rGBM have shown limited efficacy. VEGF is highly upregulated proangiogenic growth factor in GBM contributing to tumor-associated immunosuppression. Preclinical data suggests a potential dose effect of anti-VEGF therapy on immunomodulation. Hence, a combination of...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neuro Oncol
Main Authors: Ahluwalia, Manmeet, Peereboom, David, Rauf, Yasmeen, Lathia, Justin, Alban, Tyler, Schilero, Cathy, Ciolfi, Marci, LaForest-Roys, Corey, Nayak, Lakshmi, Lee, Eudocia, Wen, Patrick, Reardon, David
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2020
Assuntos:
Clinical Trials: Immunologic
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7650408/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa215.146
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados